Top

Current Neurology and Neuroscience Reports

Published in:

Open Access 01-07-2020 | Multiple Sclerosis | Demyelinating Disorders (J. Bernard and M. Cameron, Section Editor)

Cognitive Dysfunction in the Early Stages of Multiple Sclerosis—How Much and How Important?

Authors: Magdalena Oset, Mariusz Stasiolek, Mariola Matysiak

Published in: Current Neurology and Neuroscience Reports | Issue 7/2020

Abstract

Purpose of Review

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that mainly affects young adults and that is one of the leading causes of disability in this age group, with cognitive impairment occurring early in the course of the disease. This article summarizes the current knowledge about cognitive dysfunction in the early phase of MS, including biomarkers, MRI correlates, and its value as a prognostic marker.

Recent Findings

New sets of neuropsychological tests have been established to screen for cognitive dysfunction more easily and accurately. Moreover, structural changes detected by brain MRI and several biomarkers found in cerebrospinal fluid and blood serum have been recently correlated with decreased cognitive performance. Additionally, factors influencing cognition in MS, such as disease-modifying therapy, mood disorders, and lifestyle, are better described.

Summary

Cognitive impairment early in the course of MS is suggested as a prognostic factor for disease progression. However, clear-cut definitions of the early stage of MS as well as unified criteria for the diagnosis of cognitive impairment are still lacking. New and more reliable tools for evaluating cognition in MS patients should be developed and introduced into everyday practice to facilitate the implementation of effective disease-modifying therapy, cognitive rehabilitation, and lifestyle management.

•• Eijlers AJC, van Geest Q, Dekker I, Steenwijk MD, Meijer KA, Hulst HE, et al. Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study. Brain. 2018;141(9):2605–18. https://doi.org/10.1093/brain/awy202The study reports factors predisposing patients with MS to cognitive decline over a long follow-up period.CrossRefPubMed

Schulz D, Kopp B, Kunkel A, Faiss JH. Cognition in the early stage of multiple sclerosis. J Neurol. 2006;253(8):1002–10. https://doi.org/10.1007/s00415-006-0145-8.CrossRefPubMed

Trenova AG, Slavov GS, Manova MG, Aksentieva JB, Miteva LD, Stanilova SA. Cognitive impairment in multiple sclerosis. Folia Med (Plovdiv). 2016;58(3):157–63. https://doi.org/10.1515/folmed-2016-0029.CrossRef

Achiron A, Chapman J, Magalashvili D, Dolev M, Lavie M, Bercovich E, et al. Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study. PLoS One. 2013;8(8):e71058. https://doi.org/10.1371/journal.pone.0071058.CrossRefPubMedPubMedCentral

Moccia M, Lanzillo R, Palladino R, Chang KC, Costabile T, Russo C, et al. Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression. Mult Scler. 2016;22(5):659–67. https://doi.org/10.1177/1352458515599075.CrossRefPubMed

• Dorstyn DS, Roberts RM, Murphy G, Haub R. Employment and multiple sclerosis: a meta-analytic review of psychological correlates. J Health Psychol. 2019;24(1):38–51. https://doi.org/10.1177/1359105317691587This meta-analysis compares neuropsychological outcomes and quality of life between a large groups of employed and unemployed patients with MS.CrossRefPubMed

Strober L, Chiaravalloti N, Moore N, DeLuca J. Unemployment in multiple sclerosis (MS): utility of the MS Functional Composite and cognitive testing. Mult Scler. 2014;20(1):112–5. https://doi.org/10.1177/1352458513488235.CrossRefPubMed

Fernandez-Jimenez E, Arnett PA. Impact of neurological impairment, depression, cognitive function and coping on quality of life of people with multiple sclerosis: a relative importance analysis. Mult Scler. 2015;21(11):1468–72. https://doi.org/10.1177/1352458514562439.CrossRefPubMed

Achiron A, Barak Y. Cognitive changes in early MS: a call for a common framework. J Neurol Sci. 2006;245(1–2):47–51. https://doi.org/10.1016/j.jns.2005.05.019.CrossRefPubMed

10.

Feuillet L, Reuter F, Audoin B, Malikova I, Barrau K, Cherif AA, et al. Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler. 2007;13(1):124–7. https://doi.org/10.1177/1352458506071196.CrossRefPubMed

11.

Amato MP, Portaccio E, Goretti B, Zipoli V, Ricchiuti L, De Caro MF, et al. The Rao’s Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population. Mult Scler. 2006;12(6):787–93. https://doi.org/10.1177/1352458506070933.CrossRefPubMed

12.

Zipoli V, Goretti B, Hakiki B, Siracusa G, Sorbi S, Portaccio E, et al. Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes. Mult Scler. 2010;16(1):62–7. https://doi.org/10.1177/1352458509350311.CrossRefPubMed

13.

Olivares T, Nieto A, Sanchez MP, Wollmann T, Hernandez MA, Barroso J. Pattern of neuropsychological impairment in the early phase of relapsing-remitting multiple sclerosis. Mult Scler. 2005;11(2):191–7. https://doi.org/10.1191/1352458505ms1139oa.CrossRefPubMed

14.

Simioni S, Ruffieux C, Bruggimann L, Annoni JM, Schluep M. Cognition, mood and fatigue in patients in the early stage of multiple sclerosis. Swiss Med Wkly. 2007;137(35–36):496–501 2007/35/smw-11874.PubMed

15.

Migliore S, Ghazaryan A, Simonelli I, Pasqualetti P, Squitieri F, Curcio G, et al. Cognitive impairment in relapsing-remitting multiple sclerosis patients with very mild clinical disability. Behav Neurol. 2017;2017:7404289–10. https://doi.org/10.1155/2017/7404289.CrossRefPubMedPubMedCentral

16.

Amato MP, Portaccio E, Goretti B, Zipoli V, Iudice A, Della Pina D, et al. Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study. Mult Scler. 2010;16(12):1474–82. https://doi.org/10.1177/1352458510380089.CrossRefPubMed

17.

Lovera J, Kovner B. Cognitive impairment in multiple sclerosis. Curr Neurol Neurosci Rep. 2012;12(5):618–27. https://doi.org/10.1007/s11910-012-0294-3.CrossRefPubMedPubMedCentral

18.

McNicholas N, O'Connell K, Yap SM, Killeen RP, Hutchinson M, McGuigan C. Cognitive dysfunction in early multiple sclerosis: a review. QJM. 2018;111(6):359–64. https://doi.org/10.1093/qjmed/hcx070.CrossRefPubMed

19.

Strober L, Englert J, Munschauer F, Weinstock-Guttman B, Rao S, Benedict RH. Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS. Mult Scler. 2009;15(9):1077–84. https://doi.org/10.1177/1352458509106615.CrossRefPubMed

20.

Corfield F, Langdon D. A systematic review and meta-analysis of the Brief Cognitive Assessment for Multiple Sclerosis (BICAMS). Neurol Ther. 2018;7(2):287–306. https://doi.org/10.1007/s40120-018-0102-3.CrossRefPubMedPubMedCentral

21.

Korakas N, Tsolaki M. Cognitive impairment in multiple sclerosis: a review of neuropsychological assessments. Cogn Behav Neurol. 2016;29(2):55–67. https://doi.org/10.1097/WNN.0000000000000097.CrossRefPubMed

22.

Benedict RH, Duquin JA, Jurgensen S, Rudick RA, Feitcher J, Munschauer FE, et al. Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult Scler. 2008;14(7):940–6. https://doi.org/10.1177/1352458508090923.CrossRefPubMed

23.

Strober L, DeLuca J, Benedict RH, Jacobs A, Cohen JA, Chiaravalloti N, et al. Symbol digit modalities test: a valid clinical trial endpoint for measuring cognition in multiple sclerosis. Mult Scler. 2019;25(13):1781–90. https://doi.org/10.1177/1352458518808204.CrossRefPubMed

24.

Sonder JM, Burggraaff J, Knol DL, Polman CH, Uitdehaag BM. Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis. Mult Scler. 2014;20(4):481–8. https://doi.org/10.1177/1352458513501570.CrossRefPubMed

25.

Amato MP, Portaccio E, Goretti B, Zipoli V, Hakiki B, Giannini M, et al. Cognitive impairment in early stages of multiple sclerosis. Neurol Sci. 2010;31(Suppl 2):S211–4. https://doi.org/10.1007/s10072-010-0376-4.CrossRefPubMed

26.

Ruano L, Portaccio E, Goretti B, Niccolai C, Severo M, Patti F, et al. Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Mult Scler. 2017;23(9):1258–67. https://doi.org/10.1177/1352458516674367.CrossRefPubMed

27.

Johnen A, Landmeyer NC, Burkner PC, Wiendl H, Meuth SG, Holling H. Distinct cognitive impairments in different disease courses of multiple sclerosis—a systematic review and meta-analysis. Neurosci Biobehav Rev. 2017;83:568–78. https://doi.org/10.1016/j.neubiorev.2017.09.005.CrossRefPubMed

28.

Brissart H, Morele E, Baumann C, Perf ML, Leininger M, Taillemite L, et al. Cognitive impairment among different clinical courses of multiple sclerosis. Neurol Res. 2013;35(8):867–72. https://doi.org/10.1179/1743132813Y.0000000232.CrossRefPubMed

29.

Skrobas U, Brudkowska Ż, Gerage R, Kitowska M, Karakuła-Juchnowicz H. Zaburzenia funkcji poznawczych jako wczesny marker diagnostyczny w stwardnieniu rozsianym. In: Nyćkowiak J, Leśny J, editors. Badania i Rozwój Młodych Naukowców w Polsce. Poznań: Młodzi Naukowcy; 2018.

30.

Muckschel M, Beste C, Ziemssen T. Immunomodulatory treatments and cognition in MS. Acta Neurol Scand. 2016;134(Suppl 200):55–9. https://doi.org/10.1111/ane.12656.CrossRefPubMed

31.

Patti F, Morra VB, Amato MP, Trojano M, Bastianello S, Tola MR, et al. Subcutaneous interferon beta-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. PLoS One. 2013;8(8):e74111. https://doi.org/10.1371/journal.pone.0074111.CrossRefPubMedPubMedCentral

32.

Mattioli F, Stampatori C, Bellomi F, Scarpazza C, Capra R. Natalizumab significantly improves cognitive impairment over three years in MS: pattern of disability progression and preliminary MRI findings. PLoS One. 2015;10(7):e0131803. https://doi.org/10.1371/journal.pone.0131803.CrossRefPubMedPubMedCentral

33.

Planche V, Gibelin M, Cregut D, Pereira B, Clavelou P. Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis. Eur J Neurol. 2016;23(2):282–9. https://doi.org/10.1111/ene.12715.CrossRefPubMed

34.

Kunkel A, Fischer M, Faiss J, Dahne D, Kohler W, Faiss JH. Impact of natalizumab treatment on fatigue, mood, and aspects of cognition in relapsing-remitting multiple sclerosis. Front Neurol. 2015;6:97. https://doi.org/10.3389/fneur.2015.00097.CrossRefPubMedPubMedCentral

35.

Miller E, Morel A, Redlicka J, Miller I, Saluk J. Pharmacological and non-pharmacological therapies of cognitive impairment in multiple sclerosis. Curr Neuropharmacol. 2018;16(4):475–83. https://doi.org/10.2174/1570159X15666171109132650.CrossRefPubMedPubMedCentral

36.

Della Corte M, Santangelo G, Bisecco A, Sacco R, Siciliano M, d'Ambrosio A, et al. A simple measure of cognitive reserve is relevant for cognitive performance in MS patients. Neurol Sci. 2018;39(7):1267–73. https://doi.org/10.1007/s10072-018-3422-2.CrossRefPubMed

37.

Benedict RH, Morrow SA, Weinstock Guttman B, Cookfair D, Schretlen DJ. Cognitive reserve moderates decline in information processing speed in multiple sclerosis patients. J Int Neuropsychol Soc. 2010;16(5):829–35. https://doi.org/10.1017/S1355617710000688.CrossRefPubMed

38.

Amato MP, Razzolini L, Goretti B, Stromillo ML, Rossi F, Giorgio A, et al. Cognitive reserve and cortical atrophy in multiple sclerosis: a longitudinal study. Neurology. 2013;80(19):1728–33. https://doi.org/10.1212/WNL.0b013e3182918c6f.CrossRefPubMed

39.

Sumowski JF, Rocca MA, Leavitt VM, Dackovic J, Mesaros S, Drulovic J, et al. Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS. Neurology. 2014;82(20):1776–83. https://doi.org/10.1212/WNL.0000000000000433.CrossRefPubMedPubMedCentral

40.

Barbu RM, Berard JA, Gresham LM, Walker LAS. Longitudinal stability of cognition in early-phase relapsing-remitting multiple sclerosis: does cognitive reserve play a role? Int J MS Care. 2018;20(4):173–9. https://doi.org/10.7224/1537-2073.2016-073.CrossRefPubMedPubMedCentral

41.

Boeschoten RE, Braamse AMJ, Beekman ATF, Cuijpers P, van Oppen P, Dekker J, et al. Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci. 2017;372:331–41. https://doi.org/10.1016/j.jns.2016.11.067.CrossRefPubMed

42.

Golan D, Doniger GM, Wissemann K, Zarif M, Bumstead B, Buhse M, et al. The impact of subjective cognitive fatigue and depression on cognitive function in patients with multiple sclerosis. Mult Scler. 2018;24(2):196–204. https://doi.org/10.1177/1352458517695470.CrossRefPubMed

43.

Nunnari D, De Cola MC, D'Aleo G, Rifici C, Russo M, Sessa E, et al. Impact of depression, fatigue, and global measure of cortical volume on cognitive impairment in multiple sclerosis. Biomed Res Int. 2015;2015:519785–7. https://doi.org/10.1155/2015/519785.CrossRefPubMedPubMedCentral

44.

Landro NI, Celius EG, Sletvold H. Depressive symptoms account for deficient information processing speed but not for impaired working memory in early phase multiple sclerosis (MS). J Neurol Sci. 2004;217(2):211–6. https://doi.org/10.1016/j.jns.2003.10.012.CrossRefPubMed

45.

Morrow SA, Rosehart H, Pantazopoulos K. Anxiety and depressive symptoms are associated with worse performance on objective cognitive tests in MS. J Neuropsychiatr Clin Neurosci. 2016;28(2):118–23. https://doi.org/10.1176/appi.neuropsych.15070167.CrossRef

46.

Gill S, Santo J, Blair M, Morrow SA. Depressive symptoms are associated with more negative functional outcomes than anxiety symptoms in persons with multiple sclerosis. J Neuropsychiatr Clin Neurosci. 2019;31(1):37–42. https://doi.org/10.1176/appi.neuropsych.18010011.CrossRef

47.

Tur C. Fatigue management in multiple sclerosis. Curr Treat Options Neurol. 2016;18(6):26. https://doi.org/10.1007/s11940-016-0411-8.CrossRefPubMedPubMedCentral

48.

Berard JA, Smith AM, Walker LAS. A longitudinal evaluation of cognitive fatigue on a task of sustained attention in early relapsing-remitting multiple sclerosis. Int J MS Care. 2018;20(2):55–61. https://doi.org/10.7224/1537-2073.2016-106.CrossRefPubMedPubMedCentral

49.

Pettersen JA. Does high dose vitamin D supplementation enhance cognition?: a randomized trial in healthy adults. Exp Gerontol. 2017;90:90–7. https://doi.org/10.1016/j.exger.2017.01.019.CrossRefPubMed

50.

Darwish H, Haddad R, Osman S, Ghassan S, Yamout B, Tamim H, et al. Effect of vitamin D replacement on cognition in multiple sclerosis patients. Sci Rep. 2017;7:45926. https://doi.org/10.1038/srep45926.CrossRefPubMedPubMedCentral

51.

Ozcan ME, Ince B, Bingol A, Erturk S, Altinoz MA, Karadeli HH, et al. Association between smoking and cognitive impairment in multiple sclerosis. Neuropsychiatr Dis Treat. 2014;10:1715–9. https://doi.org/10.2147/NDT.S68389.CrossRefPubMedPubMedCentral

52.

Ozakbas S, Turkoglu R, Tamam Y, Terzi M, Taskapilioglu O, Yucesan C, et al. Prevalence of and risk factors for cognitive impairment in patients with relapsing-remitting multiple sclerosis: multi-center, controlled trial. Mult Scler Relat Disord. 2018;22:70–6. https://doi.org/10.1016/j.msard.2018.03.009.CrossRefPubMed

53.

Rocca MA, Amato MP, De Stefano N, Enzinger C, Geurts JJ, Penner I-K, et al. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol. 2015;14(3):302–17. https://doi.org/10.1016/s1474-4422(14)70250-9.CrossRefPubMed

54.

Summers M, Swanton J, Fernando K, Dalton C, Miller DH, Cipolotti L, et al. Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease. J Neurol Neurosurg Psychiatry. 2008;79(8):955–8. https://doi.org/10.1136/jnnp.2007.138685.CrossRefPubMed

55.

Reuter F, Zaaraoui W, Crespy L, Faivre A, Rico A, Malikova I, et al. Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2011;82(10):1157–9. https://doi.org/10.1136/jnnp.2010.213744.CrossRefPubMed

56.

Wybrecht D, Reuter F, Pariollaud F, Zaaraoui W, Le Troter A, Rico A, et al. New brain lesions with no impact on physical disability can impact cognition in early multiple sclerosis: a ten-year longitudinal study. PLoS One. 2017;12(11):e0184650. https://doi.org/10.1371/journal.pone.0184650.CrossRefPubMedPubMedCentral

57.

Papadopoulou A, Muller-Lenke N, Naegelin Y, Kalt G, Bendfeldt K, Kuster P, et al. Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis. Mult Scler. 2013;19(10):1290–6. https://doi.org/10.1177/1352458513475490.CrossRefPubMed

58.

Khalil M, Enzinger C, Langkammer C, Petrovic K, Loitfelder M, Tscherner M, et al. Cognitive impairment in relation to MRI metrics in patients with clinically isolated syndrome. Mult Scler. 2011;17(2):173–80. https://doi.org/10.1177/1352458510384009.CrossRefPubMed

59.

Kolber P, Montag S, Fleischer V, Luessi F, Wilting J, Gawehn J, et al. Identification of cortical lesions using DIR and FLAIR in early stages of multiple sclerosis. J Neurol. 2015;262(6):1473–82. https://doi.org/10.1007/s00415-015-7724-5.CrossRefPubMed

60.

Zivadinov R, Sepcic J, Nasuelli D, De Masi R, Bragadin LM, Tommasi MA, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001;70(6):773–80. https://doi.org/10.1136/jnnp.70.6.773.CrossRefPubMedPubMedCentral

61.

Hanken K, Eling P, Klein J, Klaene E, Hildebrandt H. Different cortical underpinnings for fatigue and depression in MS? Mult Scler Relat Disord. 2016;6:81–6. https://doi.org/10.1016/j.msard.2016.02.005.CrossRefPubMed

62.

Steenwijk MD, Geurts JJ, Daams M, Tijms BM, Wink AM, Balk LJ, et al. Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant. Brain. 2016;139(Pt 1):115–26. https://doi.org/10.1093/brain/awv337.CrossRefPubMed

63.

Nygaard GO, Walhovd KB, Sowa P, Chepkoech JL, Bjornerud A, Due-Tonnessen P, et al. Cortical thickness and surface area relate to specific symptoms in early relapsing-remitting multiple sclerosis. Mult Scler. 2015;21(4):402–14. https://doi.org/10.1177/1352458514543811.CrossRefPubMed

64.

Rojas JI, Murphy G, Sanchez F, Patrucco L, Fernandez MC, Miguez J, et al. Thalamus volume change and cognitive impairment in early relapsing-remitting multiple sclerosis patients. Neuroradiol J. 2018;31(4):350–5. https://doi.org/10.1177/1971400918781977.CrossRefPubMedPubMedCentral

65.

Houtchens MK, Benedict RH, Killiany R, Sharma J, Jaisani Z, Singh B, et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology. 2007;69(12):1213–23. https://doi.org/10.1212/01.wnl.0000276992.17011.b5.CrossRefPubMed

66.

Goncalves LI, Dos Passos GR, Conzatti LP, Burger JLP, Tomasi GH, Zandona ME, et al. Correlation between the corpus callosum index and brain atrophy, lesion load, and cognitive dysfunction in multiple sclerosis. Mult Scler Relat Disord. 2018;20:154–8. https://doi.org/10.1016/j.msard.2018.01.015.CrossRefPubMed

67.

Yaldizli O, Penner IK, Frontzek K, Naegelin Y, Amann M, Papadopoulou A, et al. The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients. Mult Scler. 2014;20(3):356–64. https://doi.org/10.1177/1352458513496880.CrossRefPubMed

68.

Planche V, Ruet A, Coupe P, Lamargue-Hamel D, Deloire M, Pereira B, et al. Hippocampal microstructural damage correlates with memory impairment in clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler. 2017;23(9):1214–24. https://doi.org/10.1177/1352458516675750.CrossRefPubMed

69.

Planche V, Koubiyr I, Romero JE, Manjon JV, Coupe P, Deloire M, et al. Regional hippocampal vulnerability in early multiple sclerosis: dynamic pathological spreading from dentate gyrus to CA1. Hum Brain Mapp. 2018;39(4):1814–24. https://doi.org/10.1002/hbm.23970.CrossRefPubMedPubMedCentral

70.

Faiss JH, Dahne D, Baum K, Deppe R, Hoffmann F, Kohler W, et al. Reduced magnetisation transfer ratio in cognitively impaired patients at the very early stage of multiple sclerosis: a prospective, multicenter, cross-sectional study. BMJ Open. 2014;4(4):e004409. https://doi.org/10.1136/bmjopen-2013-004409.CrossRefPubMedPubMedCentral

71.

Deloire MS, Salort E, Bonnet M, Arimone Y, Boudineau M, Amieva H, et al. Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005;76(4):519–26. https://doi.org/10.1136/jnnp.2004.045872.CrossRefPubMedPubMedCentral

72.

Sepulcre J, Murie-Fernandez M, Salinas-Alaman A, Garcia-Layana A, Bejarano B, Villoslada P. Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS. Neurology. 2007;68(18):1488–94. https://doi.org/10.1212/01.wnl.0000260612.51849.ed.CrossRefPubMed

73.

El Ayoubi NK, Ghassan S, Said M, Allam J, Darwish H, Khoury SJ. Retinal measures correlate with cognitive and physical disability in early multiple sclerosis. J Neurol. 2016;263(11):2287–95. https://doi.org/10.1007/s00415-016-8271-4.CrossRefPubMed

74.

Harris VK, Sadiq SA. Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making. Mol Diagn Ther. 2009;13(4):225–44. https://doi.org/10.2165/11313470-000000000-00000 10.1007/bf03256329.CrossRefPubMed

75.

Cai L, Huang J. Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study. Neuropsychiatr Dis Treat. 2018;14:2241–54. https://doi.org/10.2147/NDT.S173280.CrossRefPubMedPubMedCentral

76.

Disanto G, Barro C, Benkert P, Naegelin Y, Schadelin S, Giardiello A, et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857–70. https://doi.org/10.1002/ana.24954.CrossRefPubMedPubMedCentral

77.

Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler. 2012;18(5):552–6. https://doi.org/10.1177/1352458512443092.CrossRefPubMed

78.

Kuhle J, Leppert D, Petzold A, Regeniter A, Schindler C, Mehling M, et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology. 2011;76(14):1206–13. https://doi.org/10.1212/WNL.0b013e31821432ff.CrossRefPubMed

79.

Tortorella C, Direnzo V, Taurisano P, Romano R, Ruggieri M, Zoccolella S, et al. Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis. Mult Scler. 2015;21(4):396–401. https://doi.org/10.1177/1352458514546789.CrossRefPubMed

80.

• Quintana E, Coll C, Salavedra-Pont J, Munoz-San Martin M, Robles-Cedeno R, Tomas-Roig J, et al. Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain. Eur J Neurol. 2018;25(9):1189–91. https://doi.org/10.1111/ene.13687The authors showed association of CSF biomarkers with results of neuropsychological tests of MS patients.CrossRefPubMed

81.

Modvig S, Degn M, Roed H, Sorensen TL, Larsson HB, Langkilde AR, et al. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult Scler. 2015;21(14):1761–70. https://doi.org/10.1177/1352458515574148.CrossRefPubMed

82.

Mollgaard M, Degn M, Sellebjerg F, Frederiksen JL, Modvig S. Cerebrospinal fluid chitinase-3-like 2 and chitotriosidase are potential prognostic biomarkers in early multiple sclerosis. Eur J Neurol. 2016;23(5):898–905. https://doi.org/10.1111/ene.12960.CrossRefPubMed

83.

Hankomaki E, Multanen J, Kinnunen E, Hamalainen P. The progress of cognitive decline in newly diagnosed MS patients. Acta Neurol Scand. 2014;129(3):184–91. https://doi.org/10.1111/ane.12161.CrossRefPubMed

84.

Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol. 2001;58(10):1602–6. https://doi.org/10.1001/archneur.58.10.1602.CrossRefPubMed

85.

•• Pitteri M, Romualdi C, Magliozzi R, Monaco S, Calabrese M. Cognitive impairment predicts disability progression and cortical thinning in MS: an 8-year study. Mult Scler. 2017;23(6):848–54. https://doi.org/10.1177/1352458516665496The study reports utility of cognitive evaluation early in the course of MS as a prognostic factor for progression of the disease.CrossRefPubMed

86.

Deloire M, Ruet A, Hamel D, Bonnet M, Brochet B. Early cognitive impairment in multiple sclerosis predicts disability outcome several years later. Mult Scler. 2010;16(5):581–7. https://doi.org/10.1177/1352458510362819.CrossRefPubMed

Title: Cognitive Dysfunction in the Early Stages of Multiple Sclerosis—How Much and How Important?
Authors: Magdalena Oset
Mariusz Stasiolek
Mariola Matysiak
Publication date: 01-07-2020
Publisher: Springer US
Keywords: Multiple Sclerosis
Biomarkers
Published in: Current Neurology and Neuroscience Reports / Issue 7/2020
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-020-01045-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cognitive Dysfunction in the Early Stages of Multiple Sclerosis—How Much and How Important?

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 7/2020

Novel Therapies for Glioblastoma

The Role of Arachnoid Granulations and the Glymphatic System in the Pathophysiology of Idiopathic Intracranial Hypertension

Advances in Management of Brain and Leptomeningeal Metastases

Sleep and Sleep Disruption in Amyotrophic Lateral Sclerosis

Sleep Disturbances in Patients with Autoimmune Encephalitis

Impact of Age on Multiple Sclerosis Disease Activity and Progression